Iconovo

Iconovo AB (publ) develops and licenses inhalation devices in Sweden. It develops ICOres, a flexible multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; ICOone single-dose disposable dry powder inhaler; and ICOone nasal single-dose dry powder inhaler now for nasal use. It serves generic companies. The company has an agreement with Immune System Regulation AB for the development of an inhaled covid-19 vaccine in Iconovo's inhaler ICOone; and Respiratorius to develop dry powder inhalation product. Iconovo AB (publ) was founded in 2013 and is based in Lund, Sweden.

Iconovo's mission is to make life-changing medical solutions accessible to everyone. Our solutions are designed to enable better and more efficient drug delivery, empowering healthcare professionals and their patients to achieve optimal outcomes with improved compliance.

Iconovo's vision is to be the world's premier provider of smart inhaler solutions. We strive to provide solutions that facilitate more efficient, economical, and accessible delivery of specialized medications and treatments, making healthcare more accessible to all.

Iconovo has been the recipient of numerous awards and accolades throughout its existence, including being nominated for the prestigious Swedish Medical Engineering of the Year Award in 2017 and winning the 2019 Red Herring Top 100 Europe Award. We have also been featured in several publications, including Forbes, TechCrunch, and The Guardian.